Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Assets (2016 - 2026)

Intellia Therapeutics has reported Other Non-Current Assets over the past 11 years, most recently at $1.1 million for Q1 2026.

  • Quarterly Other Non-Current Assets fell 64.82% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, down 64.82% year-over-year, with the annual reading at $978000.0 for FY2025, 74.18% down from the prior year.
  • Other Non-Current Assets was $1.1 million for Q1 2026 at Intellia Therapeutics, up from $978000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $4.5 million in Q4 2023 and troughed at $978000.0 in Q4 2025.
  • The 4-year median for Other Non-Current Assets is $3.2 million (2024), against an average of $3.0 million.
  • The largest YoY upside for Other Non-Current Assets was 10.58% in 2025 against a maximum downside of 74.18% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $4.5 million in 2023, then decreased by 16.16% to $3.8 million in 2024, then crashed by 74.18% to $978000.0 in 2025, then rose by 7.57% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Other Non-Current Assets are $1.1 million (Q1 2026), $978000.0 (Q4 2025), and $2.9 million (Q3 2025).